Pfizer and Valneva's Lyme Vaccine Candidate Gets EMA Review Validation
Pfizer and Valneva’s Lyme disease vaccine candidate receives validation from the European Medicines Agency (EMA), supported by more than 70 percent efficacy in the phase 3 VALOR trial.
EMA Validation | 14/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy